With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|MLL-based chromosomal translocations in the pathogenesis of childhood leukemia.||Children's Mercy / Erin Guest||Young Investigator Grants||2009||Missouri|
|Identifying novel biomarkers for risk stratification in t-cell acute lymphoblastic leukemia (ALL).||University of California San Francisco / Michelle Hermiston, MD, PhD||Young Investigator Grants||2009||California|
|GSTM4, a novel target for treating Ewing sarcoma.||Huntsman Cancer Institute / Wen Luo||Young Investigator Grants||2009||Utah|
|Identification of proteins interacting with ALK in neuroblastoma.||Dana-Farber Cancer Institute / Rani George||Young Investigator Grants||2009||Massachusetts|
|DFMO-based combination therapy for the treatment of advanced stage neuroblastoma.||Cancer Research Center of Hawaii / Dana-Lynn Koomoa||Young Investigator Grants||2009||Hawaii|
|Targeting wnt in synovial sarcoma models.||Vanderbilt University Medical Center / Josiane Eid||Innovation Grants||2009||Tennessee|
|Pharmacogenomics of childhood AML susceptibility and treatment response.||Children's Hospital of Philadelphia / Richard Aplenc||Innovation Grants||2009||Pennsylvania|
|Targeted regulation of acetylation as novel therapy for Ewing sarcoma.||Georgetown University / Jeffrey Toretsky||Innovation Grants||2009||District of Columbia|
|Epigenetic manipulation of leukemia.||Cincinnati Children's Hospital Medical Center / H. Leighton Grimes||Innovation Grants||2009||Ohio|
|Adaptation of acute lymphoblastic leukemia (ALL) to the post-transplant allogeneic environment.||University of Rochester / Craig Mullen||Innovation Grants||2009||New York|